Matthew J Martin et al.
Oncotarget, 7(52), 86313-86325 (2016-11-20)
Metabolic plasticity is an emerging hallmark of cancer, and increased glycolysis is often observed in transformed cells. Small molecule inhibitors that target driver oncogenes can potentially inhibit the glycolytic pathway. Osimertinib (AZD9291) is a novel EGFR tyrosine kinase inhibitor (TKI)...
Linda Helbig et al.
Radiation oncology (London, England), 9, 207-207 (2014-09-23)
The transcription factor hypoxia-inducible factor-1 (HIF-1) pathway plays an important role in tumor response to cytotoxic treatments. We investigated the effects of a novel small molecule inhibitor of mitochondrial complex I and hypoxia-induced HIF-1 activity BAY-87-2243, on tumor microenvironment and...
Richard A Noble et al.
Haematologica, 102(7), 1247-1257 (2017-04-08)
Inhibition of monocarboxylate transporter 1 has been proposed as a therapeutic approach to perturb lactate shuttling in tumor cells that lack monocarboxylate transporter 4. We examined the monocarboxylate transporter 1 inhibitor AZD3965, currently in phase I clinical studies, as a...
Emerging strategies of cancer therapy based on ferroptosis
Shen z, et al.
Advanced Materials, 30(12), 1704007-1704007 (2018)
Gina-Eva Görtz et al.
The Journal of clinical endocrinology and metabolism, 101(12), 4834-4842 (2016-09-10)
In Graves' ophthalmopathy (GO), inflammation with tissue expansion in a closed compartment like the bony orbit and smoking may cause tissue hypoxia. In this study, we investigated whether hypoxia-inducible factor-1 (HIF-1) action impacts on tissue remodeling in GO with the...